Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Godaddy Inc (GDDY) vs Heron Therapeutics Inc (HRTX) Price & Performance

Godaddy IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Godaddy Inc vs Heron Therapeutics Inc — how do they compare? Godaddy Inc trades at $92.36 (market cap $11.49B), while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: Godaddy Inc is far larger — about 186.9× Heron Therapeutics Inc's market cap, and Godaddy Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

GDDYHRTX
Market Cap
$11.49B$61.47M
Sector
TechnologyHealth
52-Week High
$148.88$1.49
52-Week Low
$75.07$0.32
Enterprise Value
$14.18B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Godaddy Inc

GoDaddy (GDDY) trades at $90.78, down 0.78% on the day, with a bearish technical signal and mixed sentiment due to ongoing securities investigations. Fundamentally, the company shows strength with consistent earnings beats, revenue growth to $4.95B in 2025, and robust profitability margins. The stock trades at a P/E of 13.48, below the sector average, while analyst consensus targets $112.13, implying significant upside.

The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term volatility is likely from legal overhangs and technical resistance. Key risks include potential litigation outcomes and competitive pressures in web services. Upside hinges on continued execution and clearing regulatory concerns.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Godaddy Inc

GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.

Read more on GDDY

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX